How to protect the first ‘CRISPR babies’ prompts ethical debate
By Smriti Mallapaty,
Nature
| 02. 25. 2022
Photo of He Jiankui licensed for reuse under CC BY 3.0
Two prominent bioethicists in China are calling on the government to set up a research centre dedicated to ensuring the well-being of the first children born with edited genomes. Scientists have welcomed the discussion, but many are concerned that the pair’s approach would lead to unnecessary surveillance of the children.
The proposal comes ahead of the possibly imminent release from prison of He Jiankui, the researcher who in 2018 shocked the world by announcing that he had created babies with altered genomes. He’s actions were widely condemned by scientists around the world, who called for a global moratorium on editing embryos destined for implantation. Several ethics committees have since concluded that the technology should not be used to make changes that can be passed on.
Researchers say that the latest proposal, in a document by Qiu Renzong at the Chinese Academy of Social Science in Beijing and Lei Ruipeng at the Huazhong University of Science and Technology in Wuhan, is the first to discuss how to manage the children’s...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...